Glaxo Confident In Output From Its Revamped R&D Engine
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s biggest drug maker updated the investment community on its pipeline prospects Dec. 3, outlining a timescale of three pipeline “waves” that will include pivotal clinical trial results on up to 14 medicines in the next two years.
You may also be interested in...
GSK R&D President Patrick Vallance On Increasing R&D Productivity: An Interview With PharmAsia News (Part 2 of 2)
An R&D model aimed at bringing the pressure and promise of startups to life within GlaxoSmithKline PLC continues to be tweaked, according to Patrick Vallance, president of pharmaceuticals R&D. He sat down with PharmAsia News during a recent visit to Singapore to give an overview of the company’s strategy.
GSK R&D President Patrick Vallance On Increasing R&D Productivity: An Interview With PharmAsia News (Part 1 of 2)
An R&D model aimed at bringing the pressure and promise of startups to life within GlaxoSmithKline PLC continues to be tweaked, according to Patrick Vallance, president of pharmaceuticals R&D. He sat down with PharmAsia News during a recent visit to Singapore to give an overview of the company’s strategy.
GSK Highlights Easy Pen Delivery Of Albiglutide As FDA Begins Review
The GLP-1 class is set for huge growth in the diabetes market, but competition is going to be tough. GlaxoSmithKline explains why its newly submitted once-weekly GLP-1 agonist albiglutide has what it takes to succeed.